Amgen receives FDA approval for Repatha

Repatha, Amgen's cholesterol drug, has been approved by the FDA to be used as a cardiovascular prevention medication. Data from a its Fourier trial showed that Repatha reduced heart attack risks by 27%, stroke by 21% and coronary revascularizations by 22%. With this approval, Repatha becomes the first in its class of pricey new cholesterol drugs to boast the indication.

Click here to view the entire article.